What's Happening?
Researchers have developed a new microneedle biosensor capable of real-time monitoring of kidney and liver drug clearance in a rat model. The biosensor, created by Sam Emaminejad and colleagues, uses a nanocavity-textured microneedle electrode paired
with a bioanalytical framework to translate interstitial fluid measurements into blood-equivalent pharmacokinetic parameters. The biosensor demonstrated its potential for therapeutic drug monitoring by showing concordance with blood levels of the chemotherapy drug irinotecan in healthy rats. It also detected prolonged drug half-life in rats with liver damage and lower drug clearance in rats with adenine-induced kidney injury.
Why It's Important?
This advancement in biosensor technology could revolutionize the way kidney and liver functions are monitored, offering a minimally invasive method for real-time assessment. The ability to detect changes in drug clearance before traditional blood tests could lead to earlier interventions and more personalized treatment plans for patients with kidney or liver conditions. This technology has the potential to improve patient outcomes by enabling precision dosing and providing clinicians with actionable insights into organ function.
What's Next?
The research team plans to expand the range of detectable biomarkers and translate this technology to human studies. The goal is to contextualize drug and biomarker measurements to guide clinical interventions. If successful, this biosensor could become a valuable tool in clinical settings, aiding in the management of various health conditions and improving the precision of therapeutic interventions.
